(Reuters) – Manufacturers of the 10 prescription drugs subject to price negotiations for the U.S. Medicare program have signed on to participate in the talks by the Oct. 1 deadline even as Novo Nordisk filed a lawsuit to halt the process.At least nine lawsuits were filed between June and late September seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution.
The following are key details of the lawsuits:
Company Date Location Drugs named in
filed lawsuit as
likely to be
affected by IRA
Merck & Co June 6 U.S. District Court Diabetes drugs
for the District of Januvia and
Columbia Janumet, cancer
treatment
Keytruda
The U.S. June 9 U.S. District Court NA
Chamber of for the Southern
Commerce District Of Ohio
Western Division
Bristol Myers June 16 U.S. District Court Blood thinner
Squibb for the District of Eliquis, cancer
New Jersey therapy Opdivo
Johnson & July 18 U.S. District Court Blood thinner
Johnson for the District of Xarelto
New Jersey
Pharmaceutica June 21 U.S. District Court NA
l Research For the Western
and District Of Texas
Manufacturers Austin Division
of America
Boehringer Aug 18 U.S. District Court Diabetes drug
Ingelheim for the District Of Jardiance
Connecticut
AstraZeneca Aug 25 U.S. District Court Cancer drug
For the District Of Lynparza, blood
Delaware disorder
treatment
Soliris
Novartis Sept 1 U.S. District Court Heart-failure
for the District of drug Entresto
New Jersey
Novo Nordisk Sept 29 U.S. District Court Insulin Aspart
for the District of for Diabetes
New Jersey
(Reporting by Manas Mishra, Sriparna Roy and Mariam Sunny in Bengaluru; Editing by Bill Berkrot and Sriraj Kalluvila)
